Management Team
Kurt Kessler
CEO
THE COMMERCIAL LEADER SUPPORTING THE SCIENCE
PhD in Applied Statistics with 30 years of global pharmaceutical experience
Maria Waldhoer
CSO
SCIENCE MOM
PhD with a twenty years track record in GPCR signaling with extensive experience in academia & industry.
Aurélien Rizk
CTO
THE HUMAN BEHIND THE MODELS
PhD in computer science with 10 years of experience in systems biology.
Luca Zenone
CFO/COO
ENSURING THE CLOCK KEEPS TICKING
MSc in Business Administration running all the finance, legal and operations of the company.
Prof. Dr. Jens Gobrecht
Prof. Dr. Jens Gobrecht
HEAD OF BOARD OF DIRECTORS
Prof. emeritus Laboratory for Micro- and Nanotechnology at the Paul Scherrer Institute (PSI); Co-founder of EULITHA AG; Honorary Member of the Swiss Nanoscience Institute
Dr. Aurélien Rizk
Dr. Aurélien Rizk
BOARD MEMBER
PhD Computer Science; Co-Founder and CTO InterAx Biotech; Co-Founder Algorizk
Luca Zenone
Luca Zenone
BOARD MEMBER
MSc ETH Management, Technology and Economics; Engineering and Management Consulting; Co-Founder, CFO and COO InterAx Biotech
Dr. Yiannis Monovoukas
Dr. Yiannis Monovoukas
BOARD MEMBER
Managing Partner, Falcon III and SpringTide Ventures Fund I; CEO, Helios Cardiovascular and AuraGen Aesthetics
Dr. Bettina Ernst
Dr. Bettina Ernst
BOARD MEMBER
CEO of PRECLIN Biosystems;Board member of multiple biotech companies;VP of Board of Swiss Biotech Association
Prof. Gebhard Schertler
Prof. Gebhard Schertler
HEAD OF SCIENTIFIC ADVISORY BOARD
Professor for Structural Biology ETH Zürich; Head of Biology and Chemistry at the Paul Scherrer Institute (PSI)
Dr. Martha Sommer
Dr. Martha Sommer
SCIENTIFIC ADVISOR
Institute for Medical Physics and Biophysics at the Charité Berlin; Founder of the European Research Network on Signal Transduction (ERNEST)
Prof. Michel Bouvier
Prof. Michel Bouvier
SCIENTIFIC ADVISOR
Professor for Biochemistry Université de Montréal; CEO Institute for Research in Immunology and Cancer (IRICoR), Montreal
Dr. Philipp Berger
Dr. Philipp Berger
SCIENTIFIC ADVISOR
Senior Scientist, Paul Scherrer Institute (PSI)
Dr. Chris de Graaf
Dr. Chris de Graaf
SCIENTIFIC ADVISOR
Director of Computational Chemistry, Heptares Therapeutics
Prof. Jennifer L. Whistler
Prof. Jennifer L. Whistler
SCIENTIFIC ADVISOR
Professor at the University of California, Davis; Associate Director at Center for Neuroscience
Our Story
2010
2010
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx
2011
During his PostDoc at the Paul Scherrer Institute, Aurélien Rizk plants the “Systems Biology” seed of InterAx
2014
2014
After his MSc in Management Technology and Economics, Luca Zenone plants the “Business” seed of InterAx
August 2014
The project receives 150k CHF from the ETH Foundation
December 2014
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
2015
December 2015
Martin Ostermaier, Aurélien Rizk, Luca Zenone and the Paul Scherrer Institute are awarded a 3-year technology development grant from the Swiss Commission for Technology and Innovation towards the creation of InterAx
2016
January 2016
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech
April 2016
Martin Ostermaier, Luca Zenone, Aurélien Rizk, Gebhard Schertler and Philipp Berger co-found InterAx Biotech AG
December 2016
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
2017
February 2017
Maria Waldhoer joins InterAx as Chief Scientific Officer
December 2017
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
2019
January 2019
InterAx closes a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere
April 2019
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
Now
For most recent developments, see News page
Our Story
2010
2010
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx
During his PhD at the Paul Scherrer Institute, Martin Ostermaier plants the “Arrestin” seed of InterAx
2011
During his PostDoc at the Paul Scherrer Institute, Aurélien Rizk plants the “Systems Biology” seed of InterAx
2014
2014
After his MSc in Management Technology and Economics, Luca Zenone plants the “Business” seed of InterAx
August 2014
The project receives 150k CHF from the ETH Foundation
December 2014
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
Martin Ostermaier is named Pioneer Fellow and is awarded 150,000 CHF in equity free capital
2015
December 2015
Martin Ostermaier, Aurélien Rizk, Luca Zenone and the Paul Scherrer Institute are awarded a 3-year technology development grant from the Swiss Commission for Technology and Innovation towards the creation of InterAx Biotech
2016
January 2016
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech
Martin Ostermaier, Aurélien Rizk and Luca Zenone win the Venture Kick Final with a CHF 130K Investment in InterAx Biotech
April 2016
InterAx Biotech AG is being incorporated
December 2016
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
InterAx Biotech AG closes a seed financing round with a team of Boston-based biotech investors
2017
February 2017
Maria Waldhoer joins InterAx as Chief Scientific Officer
December 2017
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
InterAx achieves milestone that triggers second part of seed investment ahead of schedule and focuses on building its proprietary systems biology platform
2019
January 2019
InterAx closes a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere
April 2019
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
InterAx Biotech has its first customer – InterAx and the Danish pharma giant Lundbeck A/S enter an agreement to enable the in-depth characterization of drug candidates using the proprietary InterAx systems biology platform.
Now
For most recent developments, see News page
